This company listing is no longer active
Biodexa Pharmaceuticals Vergangene Ertragsentwicklung
Vergangenheit Kriterienprüfungen 0/6
Biodexa Pharmaceuticals has been growing earnings at an average annual rate of 4.3%, while the Biotechs industry saw earnings growing at 12.5% annually. Revenues have been declining at an average rate of 14% per year.
Wichtige Informationen
4.3%
Wachstumsrate der Gewinne
61.2%
EPS-Wachstumsrate
| Biotechs Wachstum der Industrie | -14.6% |
| Wachstumsrate der Einnahmen | -14.0% |
| Eigenkapitalrendite | -71.6% |
| Netto-Marge | -832.1% |
| Letzte Ertragsaktualisierung | 30 Jun 2022 |
Jüngste Aktualisierungen vergangener Leistungen
Recent updates
Aufschlüsselung der Einnahmen und Ausgaben
Wie Biodexa Pharmaceuticals Geld verdient und ausgibt. Basierend auf den neuesten gemeldeten Einnahmen der letzten zwölf Monate.
Gewinn- und Umsatzhistorie
| Datum | Einnahmen | Umsatz | Allgemeine und Verwaltungskosten | F&E-Ausgaben |
|---|---|---|---|---|
| 30 Jun 22 | 1 | -5 | 3 | 0 |
| 31 Mar 22 | 1 | -5 | 3 | 0 |
| 31 Dec 21 | 1 | -5 | 3 | 0 |
| 30 Sep 21 | 1 | -7 | 3 | 2 |
| 30 Jun 21 | 1 | -8 | 3 | 2 |
| 31 Mar 21 | 0 | -15 | 4 | 1 |
| 31 Dec 20 | 0 | -22 | 4 | 0 |
| 30 Jun 20 | 0 | -22 | 5 | 0 |
| 31 Mar 20 | 1 | -16 | 5 | 0 |
| 31 Dec 19 | 1 | -9 | 4 | 0 |
| 30 Jun 19 | 2 | -9 | 4 | 0 |
| 31 Mar 19 | 2 | -10 | 4 | 0 |
| 31 Dec 18 | 2 | -10 | 4 | 0 |
| 30 Jun 18 | 1 | -11 | 4 | 0 |
| 31 Mar 18 | 1 | -11 | 4 | 0 |
| 31 Dec 17 | 1 | -12 | 4 | 0 |
| 30 Sep 17 | -3 | -1 | -7 | -5 |
| 30 Jun 17 | 4 | -18 | 10 | 6 |
| 31 Mar 17 | 6 | -19 | 14 | 7 |
| 31 Dec 16 | 1 | -6 | 3 | 0 |
| 30 Sep 16 | 5 | -17 | 12 | 10 |
| 30 Jun 16 | 4 | -13 | 13 | 6 |
Qualität der Erträge: 5MP0 is currently unprofitable.
Wachsende Gewinnspanne: 5MP0 is currently unprofitable.
Analyse von freiem Cashflow und Gewinn
Analyse des Gewinnwachstums in der Vergangenheit
Ergebnisentwicklung: 5MP0 is unprofitable, but has reduced losses over the past 5 years at a rate of 4.3% per year.
Beschleunigtes Wachstum: Unable to compare 5MP0's earnings growth over the past year to its 5-year average as it is currently unprofitable
Erträge im Vergleich zur Industrie: 5MP0 is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-17.2%).
Eigenkapitalrendite
Hohe Eigenkapitalrendite: 5MP0 has a negative Return on Equity (-71.65%), as it is currently unprofitable.